AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy'
EsoBiotec, a small privately held firm founded four years ago in Mont-Saint-Guibert, develops in-vivo cell therapies that empower the immune system to attack cancers, and could offer many more patients access to cell therapy treatments provided in minutes rather than weeks.
The deal marks the latest acquisition by Astra, which is Britain's biggest listed company valued at £186bn, as the pharmaceutical group continues to expand its global operations.
EsoBiotec's treatment uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T-cells, which program them to recognise and destroy tumour cells for cancer treatment, or tackle autoreactive cells (that target the body's own tissues or cells) for potential use in autoimmune diseases. This means cell therapies can be administered through a simple injection, and EsoBiotec describes them as 'cost-effective, off-the-shelf therapies'.
In traditional cell therapies, cells are taken from a patient, genetically modified outside the body, and then put back into the patient as a medicine after immune cell depletion, which usually takes weeks.
Susan Galbraith, the executive vice-president of oncology research and development at AstraZeneca, said: 'We believe it has the potential to transform cell therapy and will enable us to scale these innovative treatments so that many more patients around the world can access them.
'EsoBiotec will accelerate and expand the impact of our recent investments and marks a major step forward in realising our ambition to harness the full potential of cell therapy.'
EsoBiotec recently launched a clinical trial for multiple myeloma, a type of bone marrow cancer.
AstraZeneca, which fended off a hostile £69bn takeover approach from the US group Pfizer in 2014, will pay $425m initially for the Belgian company, and up to $575m based on development and regulatory milestones. It has been beefing up its drug portfolio with targeted acquisitions, such as China's Gracell Biotechnologies, which specialises in cancer therapy known as CAR-T that modifies a patient's cells to fight the disease.
AstraZeneca's biggest deal was the $39bn acquisition of the US rare disease drug developer Alexion in 2020, but it was criticised for paying a high price. Marc Dunoyer, who runs the division and is AstraZeneca's chief strategy officer, defended the deal as a 'fantastic acquisition' last month when the company took a $753m hit for scrapping one of the Alexion drugs, while two other products from the acquisition have also been abandoned.
Separately, Britain's biggest pharmaceutical group said on Monday that its Imfinzi treatment had been approved in the EU as the first and only immunotherapy for patients with limited-stage small cell lung cancer, whose disease has not progressed after platinum-based chemoradiation therapy.
Sign up to Business Today
Get set for the working day – we'll point you to all the business news and analysis you need every morning
after newsletter promotion
AstraZeneca also announced that a drug for a rare endocrine disease, hypoparathyroidism, which can lead to bone density loss and osteoporosis, had met its goal of normalising calcium levels in the blood after 24 weeks. It was well tolerated by patients, and the trial continues as planned to 52 weeks. The company acquired the medicine along with the French rare disease specialist Amolyt Pharma in a deal worth more than $1bn a year ago.
AstraZeneca also announced a licence agreement with South Korea's Alteogen to acquire the worldwide rights to its platform, to develop and commercialise subcutaneous formulations of several oncology medicines.
Injecting medicines into the fatty tissue just under the skin can offer many advantages, including time savings for patients, clinical staff and health systems.
AstraZeneca's share price reaction was muted, dipping by 0.3%.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
2 days ago
- Daily Mail
DAILY MAIL COMMENT: Keir Starmer must fight for UK drug firms
The life sciences industry is among the brightest jewels in the British economy, generating £100billion a year and employing more than 300,000 people. At its heart is the development and manufacture of pharmaceuticals, notably by AstraZeneca, which spends vast sums on research and is worth £167billion. So, if this hugely successful company were to relocate to the US, it would be a disaster both for the London Stock Exchange and the wider economy. Worryingly, this is not out of the question. AstraZeneca already sells 40 per cent of its drugs to America and, following President Donald Trump 's tariff threat, is ramping up research and production there. While there are no immediate plans to desert the UK, chief executive Pascal Soriot is said to be 'flirting' with the idea. Mr Trump's latest demand that foreign drug companies cut prices to US customers or face penalties may be an added incentive. The Left has always been highly critical of 'Big Pharma', accusing it of profiteering on the backs of NHS patients. Under Jeremy Corbyn, Labour planned to create a state-owned drug manufacturer with the power to override the patents which enable firms to make profits from their research. Only last year, Sir Keir Starmer refused to help fund a new vaccine plant in Liverpool – while pouring public money into our ailing steel industry. This Government must understand that failing to nurture AstraZeneca, GSK and others would be a catastrophic mistake. And Sir Keir should realise that while they say they want to remain in the UK, they may yet change their mind. Car lenders off hook Banks and credit providers will have heaved a huge sigh of relief yesterday after the Supreme Court ruled they will not have to pay compensation to millions of motorists who bought cars on finance without being told the dealers were receiving commission on the loan. The Treasury was also delighted with the result. Had it gone the other way, damages could have been comparable to the PPI scandal, which destabilised the financial industry for more than a decade. The court decided that dealers did not have a duty to act solely for buyers and that commissions were not a form of bribery in the legal sense, as had been alleged. However, it was not a total exoneration. Court President Lord Reed also ruled that excessive commission payments were unfair and ordered one buyer who had been charged 25 per cent of the value of the car to be repaid with interest. This opens the way to further claims. Many brokers and dealers were paid behind-the-scenes commission by lenders to sign buyers up to car finance deals, a practice deemed 'unlawful' by the Court of Appeal in October last year - a decision that was successfully appealed by lenders at the Supreme Court The dealers and lenders have escaped their worst fears, but they do not come out well. They have certainly been guilty of sharp practices even if not illegal ones. The Competition and Markets Authority must now force them to clean up their act. OAPs feel the cold In September, Rachel Reeves promised she would 'put more money in pensioners' pockets'. What she didn't say is that she would take even more out. Research shows pensioner households are an average of £800 worse off after a year of Labour thanks to higher bills – mainly owing to the Chancellor's £40billion Budget tax raid. With more taxes coming down the track to fill Labour's ever-widening financial black hole, the cost of living is set to soar further. For all Ms Reeves' promises, the elderly are in for a bitter winter.
Daily Mail
2 days ago
- Daily Mail
Trump demands UK pharmaceutical giants to lower drug costs sparking fears NHS could pay the price if they refuse
Donald Trump has demanded UK pharmaceutical giants lower prices for America and suggested charging others to make up the difference. He said if they didn't, the US would deploy 'every tool in our arsenal' to protect families from 'continued abusive drug prices', sparking fears the NHS will end up paying more. Mr Trump suggested he would use tariffs to push through higher prices if countries resisted. In May Mr Trump signed an executive order demanding drugmakers cut US medicine prices to match those abroad. Yesterday in a letter to 17 pharma companies he said he expected them to deliver on measures by September 29. He asked them to apply 'most favoured nation' pricing to Medicaid, the US health programme for people on low incomes. Mr Trump also asked drugmakers to offer new medicines at the same price in the US as in other developed countries. He said: 'Our citizens pay massively higher prices than other nations pay for the same exact pill... subsidizing socialism aboard [abroad].' British pharma companies AstraZeneca and GSK were among the recipients. Others included Eli Lilly, Johnson & Johnson, Pfizer and Sanofi. The UK Government said it would 'continue to work closely with the US to get the best deal for our pharma industry and deliver mutual benefits for both our countries'.
Scottish Sun
2 days ago
- Scottish Sun
Donald Trump vows to unleash ‘every tool in our arsenal' in price row with British drug firms
Around £16 billion was wiped off shares in the sector across Europe after the President's comments TRUMP THREAT Donald Trump vows to unleash 'every tool in our arsenal' in price row with British drug firms Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) DONALD Trump insists he will unleash 'every tool in our arsenal' if British drug companies don't cut their prices within 60 days. The US President waged war with a total of seventeen firms demanding 'binding commitments' to match the lower prices offered to developing countries. Sign up for Scottish Sun newsletter Sign up The move comes as the White House hit dozens of countries with a fresh slew of tariffs including punishing levies on neighbour Canada. Two UK drug firms, AstraZeneca and GSK, caught up in the pharma row saw their share price drop as Trump aims to lower prices for American citizens. The move could even have damaging consequences for the NHS whose leverage with suppliers due to its size could be reduced. Mr Trump has demanded the firms apply their 'most favoured nation' rates to Medicaid which is the health system for low-income Americans. READ MORE ON DONALD TRUMP GOT TRUMPED Moment Trump 'throws shade' at Meghan and Harry during Starmer press conference He said: 'Make no mistake: a collaborative effort towards achieving global pricing parity would be the most effective path for companies, the government, and American patients. In a letter to the firms, he said: 'But if you refuse to step up we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices. 'Americans are demanding lower drug prices, and they need them today.' Around £16 billion was wiped off shares in the sector across Europe as fears grow higher prices in the rest of the world will fund the US reductions. The move comes after Trump said back in May that he wanted drug prices in the US to be reduced by 80 per cent. Moment Trump 'throws shade' at Meghan and Harry during Starmer press conference But experts appeared wary that he has the authority to reduce prices and a previous effort in his first term failed in court. At the time, he said the tactics were 'subsidising socialism' abroad in paying for the same pills from the same factories, which led to spiralling prices at home. The warning came as Mr Trump signed an executive order applying a wave of tariffs to 68 countries and the European Union. Canada was hit with levies – up to 35 per cent from 25 per cent - due to its lack of co-operation in stopping flow of illegal drugs and fentanyl into America. Their PM Mark Carney said that his country was 'making historic investments in border security to arrest drag traffickers and end migrant smuggling'. Switzerland will also keep negotiating with the US after their tariff rate hit 39 per cent, which was far higher than they anticipated.
